CONNEQT secures U.S. distribution deal with Bryan Johnson’s Blueprint longevity platform
CONNEQT Health (ASX: CQT) has entered a commercial Marketing Agreement with Blueprint, a leading U.S. longevity and preventative health platform, to promote its CONNEQT Pulse Arterial Health Monitor to U.S. consumers.
Under the agreement, the CONNEQT Pulse will be featured through Blueprint’s Protocol Marketplace via a dedicated product page, referral links and promotional offers. Customers referred through Blueprint purchase directly from CONNEQT, adding a strategically aligned consumer channel that complements the Company’s existing direct-to-consumer strategy.
No financial terms, unit targets or timelines were disclosed.
Deal at a glance
-
Partner: Blueprint, a U.S. longevity and preventative health platform
-
Product promoted: CONNEQT Pulse Arterial Health Monitor (FDA-cleared)
-
Channel: dedicated CONNEQT Pulse product page within Blueprint’s Protocol Marketplace
-
Requirement: all Marketplace products must be Blueprint Certified, having been clinically reviewed against stringent quality and research standards
-
Purchase flow: customers referred through Blueprint purchase directly from CONNEQT
When big ASX news breaks, our subscribers know first
Why the Blueprint channel matters for CONNEQT
The agreement gives CONNEQT access to a consumer audience already focused on preventative health, longevity and health optimisation, a demographic that closely matches the Company’s own target customer base. Rather than replacing the direct-to-consumer model, the partnership broadens customer acquisition through a trusted health ecosystem.
Credibility is a central feature. All products listed in the Protocol Marketplace must pass clinical review by Bryan Johnson’s dedicated team of doctors and longevity researchers to become Blueprint Certified, meaning inclusion signals third-party validation against stringent research standards.
The Blueprint partnership is not the first time the CONNEQT Pulse has earned third-party validation in the U.S. market; AARP recognition for the CONNEQT Pulse came earlier in 2026, when the device was named one of the best blood pressure monitors of the year in the ‘Most Comprehensive Data’ category across a membership base exceeding 38 million adults.
CONNEQT’s commercial model continues to evolve beyond hardware sales, spanning premium digital services, cardiology reporting, enterprise healthcare solutions and a developing cloud-based cardiovascular analytics platform.
CEO Commentary
“This agreement represents another important step in expanding our commercial distribution strategy through trusted health ecosystems. By complementing our existing direct-to-consumer activities with strategically aligned partners, we believe partnerships such as Blueprint can broaden awareness of CONNEQT Pulse while providing access to consumers whose interests closely align with CONNEQT’s focus on preventative cardiovascular health,” said Craig Cooper, Chief Executive Officer of CONNEQT Health.
Understanding the longevity health market
The longevity and preventative health movement reflects a growing group of consumers who proactively monitor and optimise their health rather than treating illness reactively. Products and protocols in this category focus on measurement, prevention and long-term health optimisation.
Blueprint was founded by Bryan Johnson, a tech entrepreneur and investor turned longevity influencer. According to the announcement, Blueprint is a U.S.-based health platform offering evidence-based health products, protocols and educational content designed to support long-term health optimisation.
The CONNEQT Pulse is an arterial health monitor built on the Company’s SphygmoCor® vascular biomarker technology, used to assess vascular and cardiovascular health. Aligning a cardiovascular device with an engaged longevity audience supports customer acquisition and broadens brand awareness within a consumer segment focused on preventative care.
What comes next for CONNEQT
The partnership fits CONNEQT’s stated strategy of expanding consumer distribution through strategically aligned health platforms and trusted health ecosystems. It sits alongside the Company’s broader growth pillars, which include premium digital services, cardiology reporting, enterprise healthcare solutions and the developing cloud-based cardiovascular analytics platform.
The SphygmoCor Cloud FDA submission, lodged in June 2026, is designed to extend the commercial model well beyond hardware, targeting 510(k) clearance as a Software as a Medical Device and opening four distinct revenue pathways including Biomarker-as-a-Service licensing and enterprise population health.
The announcement does not disclose timelines, unit targets or financial guidance associated with the arrangement.
For investors, the agreement represents an incremental channel expansion aimed at broadening customer acquisition and supporting the long-term growth of the Company’s digital health platform.
Don’t Miss the Next Healthcare Breakout
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ investors already staying ahead of the market. Click the “Free Alerts” button at StockWire X to get the next market-moving announcement the moment it drops.